Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Advanced or Metastatic ER+ Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02491983
What this trial is testing

Palbociclib in Combination With Fulvestrant or Letrozole in Patients With ER+, HER2- Advanced Breast Cancer

Who this might be right for
Metastatic Breast Cancer
MedSIR 486
Early research (Phase 1)Study completedNCT02219789
What this trial is testing

Alisertib and Fulvestrant in Treating Patients With Hormone Receptor Positive Breast Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery

Who this might be right for
Estrogen Receptor PositiveProgesterone Receptor PositiveRecurrent Breast Carcinoma+3 more
Mayo Clinic 10
Testing effectiveness (Phase 2)Ended earlyNCT01151449
What this trial is testing

Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Cancer

Who this might be right for
Estrogen Receptor-negative Breast CancerHER2-negative Breast CancerMale Breast Cancer+7 more
National Cancer Institute (NCI) 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT02311933
What this trial is testing

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Who this might be right for
Recurrent Breast CarcinomaStage III Breast Cancer AJCC v7Stage IIIA Breast Cancer AJCC v7+3 more
National Cancer Institute (NCI) 81
Testing effectiveness (Phase 2)UnknownNCT00687648
What this trial is testing

Cyclophosphamide, Methotrexate, and Prednisolone With or Without Aromatase Inhibitor Therapy in Treating Postmenopausal Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
National Cancer Centre, Singapore 70
Testing effectiveness (Phase 2)Looking for participantsNCT07766018
What this trial is testing

Bridging Study of Elacestrant Monotherapy in Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Stemline Therapeutics, Inc. 70
Large-scale testing (Phase 3)Study completedNCT00944918
What this trial is testing

Study of Faslodex With or Without Concomitant Arimidex Versus Exemestane Following Progression on Non-steroidal Aromatase Inhibitors (NSAI)

Who this might be right for
Progression-free Survival
AstraZeneca 25
Early research (Phase 1)Active Not RecruitingNCT05509790
What this trial is testing

LY3484356 in Chinese Participants With Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Eli Lilly and Company 17
Early research (Phase 1)Ended earlyNCT05827614
What this trial is testing

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications

Who this might be right for
Triple Negative Breast Cancer (TNBC)High Grade Serous Ovarian CarcinomaHigh Grade Endometrial Carcinoma+9 more
Boundless Bio, Inc. 85
Large-scale testing (Phase 3)Ended earlyNCT02340221
What this trial is testing

Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 631
Testing effectiveness (Phase 2)UnknownNCT04669587
What this trial is testing

ER+/HER2- Locally Advanced or Metastatic Breast Cancer (ENZENO Study)

Who this might be right for
Estrogen Receptor-PositiveHER2-NegativeLocally Advanced Breast Cancer+1 more
EnhancedBio USA Inc. 106
Early research (Phase 1)Study completedNCT02123823
What this trial is testing

BI 836845 in Estrogen Receptor Positive Metastatic Breast Cancer

Who this might be right for
Neoplasms
Boehringer Ingelheim 164
Testing effectiveness (Phase 2)UnknownNCT05927779
What this trial is testing

Study of TFX06 in Women With Advanced Breast Cancer.

Who this might be right for
ER+, HER2- Advanced Breast CancerMetastatic Breast Cancer
Zhejiang Yangli Pharmaceutical Technology Co., Ltd. 74
Early research (Phase 1)Active Not RecruitingNCT03332797
What this trial is testing

GDC-9545 Alone or in Combination With Palbociclib and/or Luteinizing Hormone-Releasing Hormone (LHRH) Agonist in Locally Advanced or Metastatic Estrogen Receptor-Positive Breast Cancer

Who this might be right for
Breast Cancer
Genentech, Inc. 181
Early research (Phase 1)Active Not RecruitingNCT05508906
What this trial is testing

Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer

Who this might be right for
Metastatic Breast CancerER-positive Breast CancerHER2-negative Breast Cancer+2 more
Olema Pharmaceuticals, Inc. 190
Large-scale testing (Phase 3)Study completedNCT00073528
What this trial is testing

Study Comparing Lapatinib (GW572016) And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer

Who this might be right for
Breast Neoplasms
Novartis Pharmaceuticals 1,286
Early research (Phase 1)Ended earlyNCT05489679
What this trial is testing

AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Accutar Biotechnology Inc 6
Testing effectiveness (Phase 2)Active Not RecruitingNCT06428396
What this trial is testing

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)

Who this might be right for
Metastatic Breast Cancer
Merck Sharp & Dohme LLC 120
Early research (Phase 1)Active Not RecruitingNCT03900884
What this trial is testing

Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast Cancer

Who this might be right for
Breast Neoplasm Female
Peter MacCallum Cancer Centre, Australia 17
Early research (Phase 1)Active Not RecruitingNCT04188548
What this trial is testing

LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

Who this might be right for
Breast CancerAdvanced Breast CancerMetastatic Breast Cancer+1 more
Eli Lilly and Company 379
Next Page